SCHEMBL5038828

SCHEMBL5038828

Cc1ccc(-c2ccc(OBOc3ccc(-c4ccc(C)c([N+](=O)[O-])c4)cc3)cc2)cc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
TSHR P16473 2/20 0.47
RECQL P46063 2/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 9/20 0.46
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 3/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MCL1 Q07820 1/20 0.40
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177217 0.87 ALDH1A1 (0.53) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL17117159 0.85 TSHR (0.62) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL375109 0.84 MAPT (0.53) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL7190826 0.83 TSHR (0.64) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL9999827 0.80 ALDH1A1 (0.56) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL1514401 0.78 CRHBP (0.58) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL15203036 0.78 CRHBP (0.58) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL20364812 0.77 ALDH1A1 (0.53) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL31436939 0.77 ALDH1A1 (0.53) ALDH1A1TSHRRECQLCYP3A4MAPT
SCHEMBL3537270 0.76 ALDH1A1 (0.51) ALDH1A1TSHRRECQLCYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410963-B2 To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile VIA PHARMACEUTICALS, INC. (US) 2008-08-12 US disclosed
US-20070123519-A1 Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof BAY CITY CAPITAL LLC 2007-05-31 US disclosed
EP-1697332-A1 BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF NEURO3D (FR) 2006-09-06 EP disclosed
WO-2005063723-A1 BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF NEURO3D (FR) 2005-07-14 WO disclosed
EP-1548011-A1 Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof NEURO3D (FR) 2005-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123519-A1 Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof PDE12, PDE2A, PDE3A ALDH1A1 493/4885TSHR 4068/4885RECQL 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.